The Pacific Northwest (PNW) Prostate Cancer SPORE continuation grant represents a coordinated effort of four institutions with established programs and strengths in translational prostate cancer research and career development: 1) the Fred Hutchinson Cancer Research Center (FHCRC);2) the University of Washington (UW) and its affiliated institutions;3) the University of British Columbia and the Prostate Centre of Vancouver General Hospital (UBC);and, 4) Oregon Health and Sciences University (OHSU). These Seattle-, British Columbia- and Portland-based institutions have large multidisciplinary teams of investigators and laboratories dedicated to prostate cancer research and a history of working closely together within this larger milieu. The respective teams of clinicians and researchers at these institutions bring considerable scientific depth and breadth required for confronting the most challenging problems blocking progress in our ultimate goal of reducing the morbidity and mortality associated with prostate cancer. This SPORE proposal provides the blueprint for building a large coordinated translational prostate cancer effort spanning the PNW. All participating institutions have made substantial commitments toward supporting the SPORE and its innovative, translational projects: 1) A population-based cohort study to identify metastasis-modifier alleles predictive of prostate cancer progression and mortality;2) A clinical study of prostate cancer radiation resistance and associated cellular mechanisms responsible for treatment failure;3) A translational study of the role of Hsp27 inhibition to target hormone refractory prostate cancer and mechanisms of cellular response to stress;4) A neoadjuvant study to confirm preclinical data showing that combined inhibition of androgens and the IGF receptor enhance prostate cancer response;and, 5) A study of tumor response to complete androgen ablation in relation to tissue levels of androgens and AR activity. We also propose four Cores to support these projects: 1) leadership and administration;2) tissue/specimens;3) biostatistics;and 4) clinical research. In addition, we propose a Career Development Program and a Developmental Research Program that will significantly embellish and strengthen the translational goals of our prostate cancer research program and expand opportunities for engaging young as well as established investigators in our multidisciplinary environment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-10
Application #
8130556
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
2002-09-19
Project End
2013-08-31
Budget Start
2011-09-08
Budget End
2013-08-31
Support Year
10
Fiscal Year
2011
Total Cost
$2,185,000
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Gomez-Sarosi, Luis; Sun, Yu; Coleman, Ilsa et al. (2017) DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes. Mol Cancer Res 15:842-851
Urbanucci, Alfonso; Barfeld, Stefan J; Kytölä, Ville et al. (2017) Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep 19:2045-2059
Jhun, Min A; Geybels, Milan S; Wright, Jonathan L et al. (2017) Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Oncotarget 8:43035-43047
Nguyen, Holly M; Vessella, Robert L; Morrissey, Colm et al. (2017) LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. Prostate 77:654-671
Arang, Nadia; Kain, Heather S; Glennon, Elizabeth K et al. (2017) Identifying host regulators and inhibitors of liver stage malaria infection using kinase activity profiles. Nat Commun 8:1232
Lam, Hung-Ming; McMullin, Ryan; Nguyen, Holly M et al. (2017) Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. Clin Cancer Res 23:2301-2312
Guedes, Liana B; Antonarakis, Emmanuel S; Schweizer, Michael T et al. (2017) MSH2 Loss in Primary Prostate Cancer. Clin Cancer Res 23:6863-6874
Malek, Reem; Gajula, Rajendra P; Williams, Russell D et al. (2017) TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Res 77:3181-3193
Green, S M; Kaipainen, A; Bullock, K et al. (2017) Role of OATP transporters in steroid uptake by prostate cancer cells in vivo. Prostate Cancer Prostatic Dis 20:20-27
Lawless, Margaret; Gulati, Roman; Tretiakova, Maria (2017) Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. Histopathology 71:406-414

Showing the most recent 10 out of 362 publications